Keep up to date with sterna biologicals – read our latest news and find out where you can meet us

Upcoming events

BIO-Europe 2020

October 26–28, 2020
Munich, GER

J.P. Morgan 39th Annual Healthcare Conference

January 11–14, 2021
San Francisco, CA, USA

Company news

  • sterna biologicals secures EUR 12.0 million (approx. USD 13.0 million) in private placement

    Marburg, Germany, May 26, 2020

    • Proceeds to fund next Phase 2 clinical study with SB010 in moderate to severe asthma and oral formulation work for SB012 in ulcerative colitis 
    • Sterna’s approach to down-regulate master transcription factor GATA-3 using a DNAzyme (enzymatic antisense oligonucleotide) enables broad-spectrum, simultaneous intervention in key type 2 inflammatory processes 
    • Topical treatment with SB010 and SB012 is expected to become a novel, safe and efficacious therapeutic option for chronic inflammatory diseases with high unmet medical need. 


  • sterna biologicals to attend international partnering and investor conferences in November

    Marburg, Germany, November 07, 2019 
    Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announced that the Company will participate and present at the following partnering and investor conferences in November:


  • sterna biologicals invited to present at the GOODWIN - SOLEBURY TROUT - NASDAQ european biotech investor day 2019

    Marburg, Germany, 25 July 2019

    • sterna biologicals selected as one of a group of top-tier European biotech companies to present at the European Biotech Investor Day on August 1, 2019 in New York City
    • CEO Christian Pangratz to discuss the Company’s robust development progress and next phase of growth fueled by sterna’s first-in-class DNAzyme hgd40 in Phase 2 development for asthma and ulcerative colitis